Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy

被引：0

作者：

Montes, Maria Luisa ^{[1
,2
]}

Busca, Carmen ^{[1
,2
]}

Rava, Marta ^{[2
,3
]}

Bernardino, Jose Ignacio ^{[1
,2
]}

Rivero, Antonio ^{[2
,4
]}

Martin-Carbonero, Luz ^{[1
,2
]}

Canas-Ruano, Esperanza ^{[2
,5
]}

Ugarte, Sofia Ibarra ^{[6
]}

Galindo, Maria Jose ^{[7
]}

Cabello, Alfonso ^{[8
]}

Gonzalez-Garcia, Juan ^{[1
,2
]}

机构：

[1] Hosp Univ La Paz, Inst Hlth Res IdiPAZ, Serv Med Interna, Unidad VIH, Madrid, Spain

[2] Inst Salud Carlos III, Ctr Biomed Res Infect Dis CIBERINFEC CB21 13 00091, Madrid, Spain

[3] Carlos III Hlth Inst, Natl Ctr Epidemiol, Madrid, Spain

[4] Univ Cordoba UCO, Hosp Univ Reina Sofia, Dept Infect Dis, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Argentina

[5] Hosp Mar, Dept Infect Dis, Inst Hosp Mar Med Res IMIM, Barcelona 08003, Spain

[6] Hosp Univ Basurto, Serv Enfermedades Infecciosas, Bilbao, Bizkaia, Spain

[7] Hosp Clin Univ Valencia, Valencia, Spain

[8] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

来源：

AIDS | 2024年 / 38卷 / 14期

关键词：

FIBROSIS;

D O I：

10.1097/QAD.0000000000004008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated the impact of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on type 2 diabetes mellitus (DM2) using triglyceride-glucose (TyG) and Fibrosis-4 (FIB-4). The incidence of DM2 was 12.9 [95% confidence interval (CI), 16.9-9.7] and 9.8 (95% CI, 6.9-13.6) per 1000 person-years in HS-IR and LF. The prevalence of HS-IR was significantly lower at 12 and 24 months with TDF + (3TC or FTC) + RPV [hazard ratio (HR) 0.5 [95% CI, 0.3-0.8], P < 0.01 at 12 months; 0.6 [0.4-0.9], P = 0.01 at 24 months].

引用

页码：1982 / 1987

页数：6

共 50 条

[1] Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
Lingvay, Ildiko
Roe, Erin D.
Duong, Jonathan
Leonard, David
Szczepaniak, Lidia S.
JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (07) : 1059 - 1063
[2] Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes
Zib, Ivana
Jacob, Aris N.
Lingvay, Ildiko
Salinas, Karin
McGavock, Jonathan M.
Raskin, Philip
Szczepaniak, Lidia S.
JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (05) : 230 - 236
[3] Effect of insulin resistance on hepatic function in type 2 diabetes
El Oudi, M.
Ouertani, H.
Aouni, Z.
Mazigh, C.
Zidi, B.
Machghoul, S.
IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2009, 24 (03): : 121 - 125
[4] Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, Ildiko
Raskin, Philip
Szczepaniak, Lidia S.
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 137 - 142
[5] Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes
Viganò, M
Vergani, A
Trombini, P
Pozzi, M
Paleari, F
Piperno, A
GASTROENTEROLOGY, 2000, 118 (05) : 986 - 987
[6] COMPARATIVE STUDY OF ORAL ANTIDIABETIC THERAPY AND INSULIN THERAPY ON HEPATIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Hoza, Anica
Moldovan, Corina
Farcas, Dorina Maria
Pallag, Annamaria
Nemeth, Sebastian
Marc, Felicia
FARMACIA, 2018, 66 (04) : 652 - 657
[7] Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes
Petersen, KF
Dufour, S
Befroy, D
Lehrke, M
Hendler, RE
Shulman, GI
DIABETES, 2005, 54 (03) : 603 - 608
[8] Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy
Zhou, Wan
Ye, Shandong
CELL BIOLOGY INTERNATIONAL, 2018, 42 (10) : 1282 - 1291
[9] Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
Barana, L.
Nelva, A.
Scivetti, P.
Costanzo, M.
Fanelli, C. G.
ENDOCRINE, 2024, 84 (02) : 412 - 419
[10] Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
L. Barana
A. Nelva
P. Scivetti
M. Costanzo
C. G. Fanelli
Endocrine, 2024, 84 : 412 - 419

← 1 2 3 4 5 →